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Abstract
Background: The objective was to analyze the effectiveness and safety of dual therapy with rilpivirine plus boosted-
darunavir (RPV + bDRV) in real-life patients.
Methods: Observational, retrospective, multi-center study in HIV+ patients who had received RPV + bDRV for 24 weeks
to optimize/simplify their previous antiretroviral treatment. We determined the percentage of patients without virologic
failure (2 consecutive viral loads > 50 copies/mL) at 24 weeks of treatment.
Results: The study included 161 patients from 15 hospitals with median age of 49 years; 29.3% had previous AIDS stage
and median CD4+ lymphocyte nadir of 170 cells/uL. They had been diagnosed with HIV for a median of 17 years and
had received 14 years of ART, with five previous treatment combinations, and 36.6% had a history of virological failure.
The reasons for the switch were simplification/optimization (49.7%), toxicity/intolerance (17.4%), or inadequate
effectiveness of previous ART (10.6%).
Baseline VL of 50–1000 copies/mL was recorded in 25.5% of the patients. In the“intention-to-treat” analysis at 24 weeks,
87.6% of 161 patients continued the study treatment without virologic failure criteria.
In the “on treatment” analysis (excluding patients who discontinued treatment with dual therapy for any reason other
than virologic failure) the efficacy was 94.6% (141/149 patients).
Conclusions: Dual therapy with RPV + DRVb proved to be effective and safe in patients with advanced HIV infection,
long exposure to ART, low CD4 nadir, previous virologic failure, and/or history of ineffective ART.
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Background
The life expectancy of HIV-infected individuals is ap-
proaching that of the general population due to the effect-
iveness and good tolerability of new antiretroviral drugs.
The main concerns over antiretroviral therapy (ART)
are no longer efficacy and tolerance, but antiretroviral
drug-related toxicity [1], especially over the long term.
This toxicity tends to be subclinical and cumulative and
has the potential to interact with comorbidities, aging,
and other processes related to immune activation and
inflammation in HIV infection. It is mainly associated
with Nucleoside Analogue.
Reverse Transcriptase Inhibitors (NRTI) [2–8], whose
frequent use in pairs in classic Triple Therapy (TT) exerts
a synergic antiviral effect but also increases the potential
toxicity.
For this reason, nuke-sparing regimens (NSRs), that
do not include one or both NRTIs, have been developed
to reduce and prevent ART-related toxicity [9]. The de-
velopment of novel and highly effective antiretroviral
(ARV) drugs with a high genetic barrier against the de-
velopment of drug resistance, such as protease inhibitors
(PI) [10, 11], allows treatments to be simplified, with the
administration of fewer drugs. Permanent TT may no
longer be necessary and safe simplification strategies are
now available to simplify ART [12].
Numerous studies (clinical trials, observational studies,
and meta-analyses) have found that the efficacy of PI
monotherapy (MT) [13–27] and dual therapy (DT) [28–31]
with lamivudine (3TC) and boosted PIs (generally in pa-
tients without advanced HIV infection who had received
suppressive ART for at least 6–12months and/or had no
history of virologic failure [VF]) was not inferior to that of
TT [15, 17, 18, 20, 23, 24, 28–34]. Both of these simplifica-
tion strategies maintain viral suppression while avoiding the
development of resistance mutations [13–27, 35] and
controlling immune activation and chronic inflammation
[36–41], even in HIV sanctuaries and biological reservoirs
[42–48], similarly to TT and with a good cost-effectiveness
ratio [12, 49–54].
Fewer data are available on the application of DT in
patients with a less favorable profile (advanced HIV in-
fection, long exposure to ART, history of virological fail-
ures, long-term toxicity), although they have generally
proven high efficacy and a reduction of possible toxicity
[55–62].
DT with rilpivirine and boosted darunavir (RPV + bDRV)
is an attractive NSR that appears to combine both a high
efficacy and genetic barrier with a lower pill burden, good
tolerance and toxicity profile. However, despite its
utilization in clinical practice, there has been little research
on the outcomes.
With this background, we performed a retrospective
multi-center investigation to analyze the profile of
patients prescribed with this combination and study its
efficacy and safety. Confirmation that these NSRs are
safe and effective will help to consolidate them as an op-
timized alternative for ART that could improve the
long-term prognosis of HIV-infected patients and reduce
treatment costs.
Methods
Study design
An observational, retrospective, multi-center study was
conducted in HIV-infected patients who switched to DT
with rilpivirine (RPV) (25 mg, once daily) and boosted
darunavir (bDRV) (800 mg, once daily) (with either
ritonavir or cobicistat).
Objectives
The main objective of the study was to analyze the ef-
fectiveness of the DT by calculating the proportion of
patients with virologic success (defined as 24 weeks of
follow up without VF, considering VF as two consecutive
RNA HIV-1 > 50 copies/mL).
Secondary objectives were to establish: a) proportion
of patients with RNA HIV-1 < 50 copies/mL at week 24
of treatment; b) stratification of all viral load determina-
tions obtained during exposure to the DT; c) Incidence
of new adverse events; d) Impact of the DT on lympho-
cyte subpopulations, lipid profile, and liver and kidney
function; e) Analysis of possible differences in efficacy
and potential toxicity between darunavir/ritonavir (DRV/
r) and darunvir/cobicistat (DRV/c).
Inclusion criteria and variables
Patients from 15 Spanish hospitals were evaluated, with
the following inclusion criteria: infection with HIV-1,
age > 18 years, and receipt of antiretroviral treatment with
RPV + bDRV before December 31st 2015 with a minimum
follow-up period of 24 weeks. They were also required to
have a baseline viremia at switch (bVL) < 1000 copies/mL
and to have signed informed consent to retrieve data from
their medical records.
A standardized electronic database was use to collect
the following variables: age, gender, date of HIV diagno-
sis, VL at diagnosis, CD4 lymphocyte cell count at diag-
nosis, CD4 nadir, HIV stage (CDC), date of first ART,
number of previous ART combinations, previous ART,
previous VF (and ART received and genotype mutations
at time of VF), reason for switch to study combination
(toxicity, intolerance, VF, simplification/optimization or
other reasons), booster (ritonavir or cobicistat), weeks of
exposure to ritonavir and cobicistat, and HIV- 1 RNA,
CD4 cell count, and bloodwork at baseline, 4–8 weeks,
9–23 weeks, and ≥ 24 weeks.
New adverse events during exposure to DT and rea-
sons for not completing 24 weeks of follow-up were also
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collected (toxicity/intolerance, VF, voluntary drop-out,
or others).
Statistical analysis
For the first and secondary objectives of virologic efficacy, an
intention-to-treat (ITT) analysis was carried out (considering
losses as failures) as well as an on-treatment (OT) analysis,
excluding patients who discontinued treatment with the DT
for any reason other than VF (voluntary discontinuation of
treatment, toxicity/intolerance, medical decision, patient’s
decision).
Means with standard deviation, medians, and interquartile
ranges were calculated for quantitative variables and absolute
and relative frequencies for qualitative variables. After
applying the Kolgomorov-Smirnov test to check the distribu-
tion of variables, effects of the DT on change in analytical
parameters (lipids, liver and kidney function) were analyzed
using the paired samples t-test when the distribution was
normal or the signed-rank Wilcoxon test when it was not.
For bivariate analyses, the Student’s t-test was applied when
the distribution was normal and the Mann-Whitney test
when it was not. SPSS v20.0 (IBM Corp, Armonk, NY) was
used for data analyses, and the significance level was 0.05 for
all tests.
Ethical aspects
The study was approved by the regional ethics committee
of Andalusia (CCEIBA) on April 25, 2016 and participants
provided written informed consent for data from their
medical records to be collected.
Results
General description of study population
One hundred and eighty-nine patients switched to RPV+
bDRV: 28 did not meet inclusion criteria (20 with baseline
VL > 1000 copies/mL and 8 with follow-up of < 24weeks).
Therefore, the final study sample comprised 161 patients
with median age of 49 years (IQR 44–53), median time
since HIV diagnosis of 17 years (IQR 10–23), receipt of
ART for median of 14 years (IQR 6–18), and median of 5
previous ART combinations (IQR 3–7); 29.3% had a history
of AIDS (stage C or 3 according to CDC), and the median
CD4 lymphocyte nadir was 170 cells/μL (IQR 73–290)
[Table 1]. ART regimens before the switch to DT included
NRTI in 59% of patients, non-nucleoside reverse transcript-
ase inhibitors (NNRTIs) in 56.5%, protease inhibitors (PI)
in 79.5%, and integrase inhibitors (II) in 9.9%; TT had been
received by 57.1% of the patients, DT by 32.9%, and MT
by 9.9%. Of the patients on MT, the reason for switch was
optimization in 43.8% patients and VF in 43.8%; bVL was
< 50 copies/mL in 6.3%.
At baseline, 25.5% did not have suppressed HIV
viremia (baseline viral load of 50–1000 copies/mL),
although the baseline CD4 lymphocyte cell count was
618 cells/μL (IQR 370–861) [Table 1]; 36.6% (59/161)
had previous VF and data were available on the drug
therapy at the time of the VF in 51 of these, being PI in
90.2% (46/51) and 9.3% of patients had previous viro-
logical failure while receiving NNRTI. In 58.8% (30/51)
of cases, the PI was DRV. Hence, one-third of the pa-
tients in this study had experienced previous VF while
receiving PI and one-fifth (21.5%) while receiving DRV.
The main reason for the switch to a DT with RPV+ bDRV
was simplification/optimization of their ART (49.7%),
followed by previous ART toxicity (17.4%), and insufficient
effectiveness of previous ART (10.6%).
Initially, the DT boosted with ritonavir (DRV/r) was
administered to 131 patients (81.4%), 29 of whom
switched to cobicistat (DRV/c) during the first 24 weeks
of treatment. A total of 59 patients (36.6%) were exposed
to DRV/c during the study period.
Effectiveness of RPV + bDRV at 24 weeks of treatment
Figure 1 depicts the flow chart of patients through the
study. The ITT population included all 161 patients,
with a median follow up of 33 weeks. At week 24, 87.6%
(141/161) of patients continued receiving RPV + bDRV
and showed no VF criteria, while 17 patients
Table 1 General description of study population
N = 161
Age in years, median (IQR) 49 (44–53)
Male sex, n (%) 126 (78.3)
Years since HIV diagnosis, median (IQR) 17 (10–23)
CD4 nadir, median (IQR) 170 (73–290)
History of AIDS, n (%) 47 (29.3)
N° previous ART combinations, median (IQR) 5 (3–7)
Years on ART, median (IQR) 14 (6–18)
Previous ART that included, n (%):
NRTI 95 (59)
NNRTI 91 (56.5)
PI 128 (79.5)
II 16 (9.9)
ART strategy, n(%):
Triple therapy 92 (57.1)
Dual therapy 53 (32.9)
Monotherapy 16 (9.9)
Baseline VL (bVL):
< 50 copies/mL, n (%) 120 (74.5)
50–1000 copies/mL, n (%) 41 (25.5)
Baseline CD4 count, median (IQR) 618 (370–861)
IQR: interquartile range; ART: antiretroviral therapy; NRTI: nucleoside analog
reversetranscriptase inhibitors; NNRTI: non-nucleoside analog reverse-
transcriptase inhibitors; PI: protease inhibitors; II: integrase inhibitors; VL:
viral load
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discontinued this DT: 6 for mild toxicity/intolerance, 4
due to voluntary abandonment of ART, 1 by physician
decision (due to one VL > 50 copies/mL), 1 by patient de-
cision to return to previous ART and 8 VF (3 confirmed
after week 24).
Excluding the 12 patients who dropped out of the
study for reasons other than VF (population for OT ana-
lysis: 149 patients), 94.6% (141/149) completed the study
without showing VF criteria.
In 82.6% (133/161) of the study population, the VL
was < 50 copies/mL at 24 weeks (ITT analysis). In 89.3%
(133/149) of the OT population, the VL was < 50 copies/
mL at 24 weeks (OT analysis).
As shown in Table 2, genotyping was performed in
three of the total of eight patients with VF and no drug
resistance mutations were detected, while two cases
were associated with poor adherence to treatment.
Resuppression of HIV viremia was achieved in all eight
cases with no modification of the DT (3 cases) or after
switching to a TT (4 cases) or different DT (1 case).
Out of the 334 VL determinations during exposure to
RPV+ bDRV, over 105 patients-years, < 50 copies/mL were
found in 87.7% (< 20 copies/mL in 79%), 50–1000 copies/
mL in 11.1%, and > 1000 copies/mL in 1.2%; 237 of these de-
terminations were obtained during exposure to RPV+DRV/
r, with 87.3% being < 50 copies/mL, and 97 during exposure
to RPV+DRV/c, with 88.7% being < 50 copies/mL.
The last observed VL determination of the 159 pa-
tients with virologic data after the switch was < 50
copies/mL in 86.2% of patients (< 20 copies/mL in 80.5%),
between 50 and 1000 copies/mL in 12.6%, and > 1000
copies/mL in 1.3%.
During the 24 weeks of exposure to the DT, the CD4
lymphocyte cell count increased by 34 cells/mm3 from
630 cells/mL to 667 cells/mm3 (p = 0.071) and the CD4/
CD8 ratio by 0.04 from 0.75 to 0.79 (p = 0.004).
Patients with previous failure while receiving darunavir
were not more likely to present VF with the study DT
[13.3% (4/30) vs 5.5% (1/18), p = 0.348] and overall base-
line viral load > 50 copies/mL was not a predictor of VF
(9.8% vs 3.3%, p = 0.115).
We analyzed the influence of CD4 nadir on VF and
found no statistically significant differences between
those who failed and those who didn’t (257 vs 156 cells/
mm3, p = 0.470). There were also no differences in VF
rate between those who received the DT boosted with
ritonavir vs cobicistat (7,5% vs 7,1%, p = 1.000).
Safety of RPV + bDRV
Although no severe adverse events were notified, six
patients switched therapies due to mild toxicity or in-
tolerance (Table 3).
Impact of RPV + bDRV on analytical parameters (lipid
profiles, and kidney and liver functions)
Statistically significant differences between values at base-
line and 24 weeks were found in creatinine (0.944mg/dL
vs. 0.977mg/dL, p = 0.001), total cholesterol (183mg/dL vs.
Fig. 1 Flow chart of study patients
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196mg/dL, p < 0.001), HDL-cholesterol (48mg/dL vs. 52
mg/dL, p = 0.005), LDL-cholesterol (107mg/dL vs. 124mg/
dL, p = 0.003), GOT (40.9 U/L vs. 30.8 U/L, p = 0.031),
GPT (45.9 U/L vs. 30.3 U/L, p = 0.011), GGT (57.5 U/L vs.
59.4 U/L, p = 0.040), and alkaline phosphatase (98U/L vs.
93 U/L, p = 0.027) but not in total cholesterol/HDLcholes-
terol ratio (Table 4). A higher increase of LDL-cholesterol
was observed with ritonavir (+ 20mg/dL) than with cobici-
stat (+ 10mg/dL), but the difference did not reach statistical
significance (p = 0.462).
Discussion
Data obtained in this study confirm that nuke-sparing
DT with RPV + bDRV may be an acceptable alternative
to triple therapy in suppressed and stable HIV-infected
patients, as previously suggested in the PROBE CT [63].
However, the present patients generally had a long
history of exposure to HIV and ART and included
numerous cases of severe previous immunodepression
(AIDS stage and/or low CD4 nadir), VF, toxicity associ-
ated with antiretroviral drugs, and even a previous non
suppressive ART. These conditions have usually been
considered as exclusion criteria in studies of MT and DT
with 3TC. Nevertheless, the DT under study was found
to achieve and maintain viral suppression in > 90% of
the present patient population.
Despite the disadvantageous profile of our study popu-
lation, the proportion of virologic suppression obtained
Table 2 Virologic failures with RPV + bDRV
Patient Baseline VL Previous ART VL at time of VF Observations
1 33 ABC/3TC + DRV/r 81–393 Resuppression without switch (continued on RPV + bDRV)
No drug resistance mutations.
2 159 ETV + DRV/r 67–96 Switch to cART (to include omeprazol).
No genotyping.
3 759 ETV + DRV/r 560–7530 Switch to RPV+ bDRV + DTG
No genotyping.
4 210 ETV + DRV/r 191–131 Resuppression without switch (continued on RPV + bDRV)
No genotyping.
5 < 50 ETV + DRV/r 16,500 (390 five days later) Poor adherence
No switch (continued on RPV + bDRV)
No genotyping.
6 < 50 ETV + RAL + DRV/r 270–1197 Switch to ETV + DRV/r (post-switch VL of 23 copies)
No drug resistance mutations
7 < 50 ETV + RAL + ATV/r 220–612 Switch to ABC/3TC + DRV/r
No drug resistance mutations
8 95 TDF/FTC + NVP 173,000-1590 Poor adherence
No genotyping
VL: viral load; ART: antiretroviral therapy; VF: virological failure; ABC: abacavir; 3TC:
lamivudine; DRV: darunavir; bDRV: boosted darunavir; ETV: etravirine; RAL: raltegravir; RPV: rilpivirine; TDF: tenofovir; ATV: atazanavir; NVP: nevirapine; DTG:
dolutegravir
Table 3 Adverse events during the study
N (%)
Mild adverse events 6 (3.7)
Anxiety and hypercholesterolemia 1 (0.6)
Abdominal pain, dyspepsia, and asthenia 1 (0.6)
Irascibility and insomnia 1 (0.6)
Pyrosis 1 (0.6)
Sexual dysfunction 1 (0.6)
Diarrhea 1 (0.6)
Grade 3–4 adverse events 0 (0)
Table 4 Impact of the dual therapy on analytical parameters
Baseline 24 weeks P value
CD4 lymphocytes (cells/uL) 630 667 0.071*
CD4/CD8 Ratio 0.749 0.788 0.004
Creatinine (mg/dL) 0.944 0.977 0.001
Glucose (mg/dL) 95.2 96.5 0.057
Total Cholesterol/HDL 4,13 4,10 0.107
Total Cholesterol (mg/dL) 183 196 < 0.001*
HDL-cholesterol (mg/dL) 48 52 0.005
LDL-cholesterol (mg/dL) 107 124 0.003*
Triglycerides (mg/dL) 144 157 0.172
Bilirubin (mg/dL) 0.77 0.64 0.827
GOT (U/L) 40.9 30.8 0.031
GPT (U/L) 45.9 30.3 0.011
GGT (U/L) 57.5 59.4 0.040
Alkaline Phosphatase (U/L) 98 93 0.026
Hemoglobin (g/dL) 15 14.8 0.009
Platelets (×10^3/μL) 190 189 0.346
*paired samples t-test (otherwise with Wilcoxon signed-rank test)
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with this DT was similar to that obtained with TT (including
stable patients with no history of VF and with suppressed
viremia in this switch scenario). Stratification of all viral load
determinations in the entire cohort during the study period
showed similar rates of blips and VFs, and almost all of the
latter could be attributed to poor treatment adherence. No
drug resistance mutations against the protease or the inverse
transcriptase were observed in any case, and all patients
achieved viral resuppression by maintaining the DT or
adding a third drug. Although RPV has a low genetic barrier
and patients who showed VF could potentially develop resist-
ance to the drug, in this study there were no VF with real ex-
posure to the DT (multiple patients reported poor treatment
adherence) and/or high viral loads and few drug resistance
tests were performed.
This is a preliminary analysis of a cohort that we are
still following, but we believe that a ‘24 weeks Analysis’,
considering a threshold of 50 copies/mL for VF, is
enough to determine virologic effectiveness for previ-
ously suppressed patients. This is the minimum time-
frame required to prove ART’s ability to suppress viral
replication in naïve patients [64–68] and for rescue strat-
egies in patients with prior virological failure [68].
Twenty-four weeks is also the minimum timeframe
required in switch studies to consider a previous
HAART stable and effective [69, 70], and we know that
the maximum suppression of HIV viremia can be
achieved with < 20 weeks of treatment [71], that viro-
logical failures with simplification strategies occur dur-
ing the first months [72] and that this rate does not
increase with follow-up time [73].
Despite their long history of ART, the immunological
recovery was similar to that reported for TT, with an in-
crease in CD4 lymphocytes and CD4/CD8 ratio.
Tolerance of the combination was generally good, al-
though several patients asked to switch to previous or
alternative treatments due to toxicity, which was consid-
ered mild in all of these cases.
A slight increase in total cholesterol and LDL-choles-
terol levels was observed with the DT under study; how-
ever, there was also an increase in HDL-cholesterol
levels, with no change in the atherogenic index over the
24-week observation period. There was a significant
decrease in transaminase levels, implying a reduction in
the potential toxicity of this DT, which supports the idea
that NRTIs such as tenofovir could have certain level of
hepatotoxicity.
More than one-third of the patients received DRV/c
(from the start of the study in half of these cases) and
showed no difference in safety and effectiveness outcomes
with those receiving DRV/r.
Study limitations include its retrospective,
multi-center design, although the necessary data were
recovered for almost all patients. Inclusion bias was
minimized by recruiting all patients who had been pre-
scribed with the DT under study in the participating hos-
pitals. However, it was not possible to evaluate potential
long-term changes in the toxicity of this combination due
to the study design and short follow-up period.
Conclusions
Dual therapy with RPV + bDRV in the clinical setting
has proven to be effective, even in patients with
advanced HIV infection, extended exposure to ART, low
CD4 lymphocyte nadir, history of VF, and/or previous
non-suppressive ART.
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